Answers are grounded in this paper and cite their sources.
The heterogeneity of the biologic response of COPD exacerbations can be defined. Sputum IL-1β, serum CXCL10, and peripheral eosinophils are biomarkers of bacteria-, virus-, or eosinophil-associated exacerbations of COPD. Whether phenotype-specific biomarkers can be applied to direct therapy warrants further investigation.
No takes yet. Share an insight, caveat, or question.
Bafadhel et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: